Eupraxia Pharmaceuticals Inc. announced that it has appointed Mark Kowalski, MD, PhD, as the Company's Chief Medical Officer effective May 18, 2023. Dr. Kowalski has more than 20 years of experience in the pharmaceutical and biotech industry. He is a clinical leader, developing regulatory strategy and global clinical development plans for a variety of product types including small molecules, biologics (monoclonals, immunoconjugates, siRNAs) and vaccines, while working in a range of indications, including oncology, infectious diseases, urology, analgesia, allergy, rheumatology and metabolic disorders.

He brings to Eupraxia experience with clinical study design, database design and authoring protocols for Phase 1 through 3 clinical trials, as well as medical monitoring and pharmacovigilance services for Phase 1 through 4 clinical trials, plus data analysis and writing of clinical study reports. Dr. Kowalski held multiple senior roles, including Chief Medical Officer, at Sierra Oncology, a public company acquired by GSK plc in 2022 for $1.9 billion. Prior to that, he was the Chief Medical Officer and Senior Vice President at Arbutus Biopharma.

Before that, he held the same position at Tekmira, a biopharmaceutical company focused on developing therapeutics based on RNA interference utilizing lipid nanoparticle delivery technology in oncology, infectious disease, metabolic and other clinical indications. Prior to Tekmira, Dr. Kowalski worked in the oncology and inflammation therapeutic area at Gilead Sciences Inc. following Gilead's $510-million acquisition of YM BioSciences Inc., at which Dr. Kowalski had been CMO and Vice President of Regulatory Affairs. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine.

He completed his postgraduate training in internal medicine and infectious diseases at Duke University and Harvard Medical School and is Board-certified in both.